Navigation Links
Prostate Cancer Prevention Trial identifies men mostly likely to undergo challenging study procedure
Date:8/13/2014

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention a journal of the American Association for Cancer Research.

The Prostate Cancer Prevention Trial was a randomized, double-blind, placebo-controlled trial which tested the efficacy of finasteride, a drug used for prostate cancer prevention. This study was conducted by SWOG a cancer research cooperative group that designs and conducts multidisciplinary clinical trials.

Researchers at The University of Texas MD Anderson Cancer Center and the Fred Hutchinson Cancer Research Center used a systematic model to identify factors associated with men adhering to the end-of-study (EOS) biopsy requirement of the trial. The EOS biopsy, an invasive procedure that examines the cells or tissues of the prostate gland to determine if cancer is evident, is an important part of the study.

"Our study is unique because it evaluated factors prospectively associated with an invasive biopsy for a cancer prevention trial, not a cancer treatment trial," said Ellen R. Gritz, Ph.D., chair of Behavioral Science at MD Anderson, and lead author on the study.

The prevention trial was coordinated by SWOG at 219 sites involving more than 18,000 men. Participants were randomized into one of two groups; those administered finasteride and those given a placebo. Participants received educational materials about the study and biopsy procedures and were asked to attend regularly scheduled appointments throughout the trial.

Funded by the National Cancer Institute, scientists analyzed healthy men over a seven-year period to identify which factors at the six-year study mark were associated with the willingness of the participant to undergo a biopsy. The factors examined included psychosocial outcomes, participant health status, participant adherence, and characteristics of the clinical sites at which the study was conducted.

"The biopsy provided the biological specimens that could be tested to see if a man's prostate cells were cancer-free after seven years on the trial," said Carol Moinpour, Ph.D., of the Fred Hutchinson Cancer Research Center. "That is, the biopsy provided definitive information about which men had prostate cancer seven years after the study started."

Researchers were able to assess factors associated with adherence for more than 13,000 men from the trial, and analyzed factors based on whether or not study participants had been prompted for a clinical biopsy by year six of the study.

Researchers found participants were more likely to adhere to the EOS biopsy if one year prior to the biopsy they were adherent to the study drug, kept appointments and underwent required tests and were in good health. Participants who had an EOS biopsy were more likely to be adherent to the study drug at year six 84 percent. Among participants who were not biopsied, only 47 percent were adherent to the study drug. Results also showed that 98 percent of men who had an EOS biopsy had the DRE (digital rectal exam) or PSA test done at year six, compared to 75 percent of men who did not have the EOS biopsy.

"We also found that participants were more likely to adhere to biopsies if the study site that recruited the participant enrolled more than 200 participants and/or had resources for conducting activities to encourage continued participation in the trial," said Gritz.

Researchers said monitoring adherence behaviors in clinical trial participants can help identify participants at risk for noncompliance to a study requirement, and help create a model for adherence intervention strategies in future trials.

"If we are able to determine which factors are associated with good adherence to study regimens evaluating cancer prevention agents, we may be able to improve the conduct of such large trials by targeting interventions to boost adherence," said Gritz.


'/>"/>

Contact: Katrina Burton
kburton@mdanderson.org
713-792-8034
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
4. Study examines adverse effects among different radiation therapies for prostate cancer
5. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
6. Warren Buffett Has Early Stage Prostate Cancer
7. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
8. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
11. Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Prostate Cancer Prevention Trial identifies men mostly likely to undergo challenging study procedure
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: